Hartaj Singh
Stock Analyst at Oppenheimer
(1.66)
# 3,324
Out of 5,065 analysts
108
Total ratings
43.27%
Success rate
-9.31%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $17.69 | +109.16% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $755.90 | +19.06% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $126.64 | -1.30% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $426.76 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $105.00 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $12.51 | +123.82% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $474.82 | +26.36% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $23.72 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $4.69 | +113.22% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $0.98 | +6,009.98% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $2.66 | +238.35% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.76 | +2,172.73% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $10.11 | +117.61% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.53 | +42,383.66% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $16.19 | +85.30% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $17.69
Upside: +109.16%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $755.90
Upside: +19.06%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $126.64
Upside: -1.30%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $426.76
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $105.00
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $12.51
Upside: +123.82%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $474.82
Upside: +26.36%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $23.72
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $4.69
Upside: +113.22%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $0.98
Upside: +6,009.98%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.66
Upside: +238.35%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.76
Upside: +2,172.73%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $10.11
Upside: +117.61%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.53
Upside: +42,383.66%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $16.19
Upside: +85.30%